Back to Agenda
Session 3 Track C: CMC Strategies for Accelerated Approval (Fast Track, Breakthrough, PRIME, etc) of Oligonucleotide Drugs
Session Chair(s)
Fran Wincott, PhD
President, United States
There is a growing trend in the pharmaceutical industry towards accelerated development of therapeutics to address unmet medical needs. The shorter timelines coupled with increasing complexity of the development candidates presents extraordinary challenges for managing the chemistry, manufacturing, and controls activities. This session will provide a background on the existing regulatory expedited pathways. Approaches for successful clinical development, regulatory approval, and commercialization of therapeutic oligonucleotides within the framework of accelerated development will be discussed.
Learning Objective : At the conclusion of this session, participants should be able to:- Describe the different expedited pathways available
- Understand CMC strategies to facilitate successful accelerated development
Speaker(s)
Olen M. Stephens, PhD
Chemist Reviewer, CMC Reviewer, CDER/OPQ/ONDP, FDA, United States
CMC Strategies for Accelerated Approval (Development) of Oligonucleotide Drugs
Nicole Del Canto
Director, Global Regulatory CMC, Biogen Inc., United States
Speaker
Veronika Jekerle, PhD, RPh
Head of Pharmaceutical Quality, European Medicines Agency, Netherlands
Speaker
Benjamin Stevens, MPH
Senior Director, Regulatory Affairs CMC Policy and Advocacy, Alnylam Pharmaceuticals, Inc., United States
Panelist
Have an account?